Annual CFI
-$57.35 M
-$73.02 M-466.08%
December 31, 2023
Summary
- As of February 8, 2025, VYNE annual cash flow from investing activities is -$57.35 million, with the most recent change of -$73.02 million (-466.08%) on December 31, 2023.
- During the last 3 years, VYNE annual CFI has fallen by -$146.46 million (-164.37%).
- VYNE annual CFI is now -164.37% below its all-time high of $89.11 million, reached on December 31, 2020.
Performance
VYNE Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$4.82 M
-$23.84 M-125.36%
September 30, 2024
Summary
- As of February 8, 2025, VYNE quarterly cash flow from investing activities is -$4.82 million, with the most recent change of -$23.84 million (-125.36%) on September 30, 2024.
- Over the past year, VYNE quarterly CFI has dropped by -$23.84 million (-125.36%).
- VYNE quarterly CFI is now -107.31% below its all-time high of $65.98 million, reached on March 31, 2020.
Performance
VYNE Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$51.73 M
-$4.82 M-10.29%
September 30, 2024
Summary
- As of February 8, 2025, VYNE TTM cash flow from investing activities is -$51.73 million, with the most recent change of -$4.82 million (-10.29%) on September 30, 2024.
- Over the past year, VYNE TTM CFI has dropped by -$4.82 million (-10.29%).
- VYNE TTM CFI is now -151.63% below its all-time high of $100.18 million, reached on September 30, 2020.
Performance
VYNE TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
VYNE Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -466.1% | -125.4% | -10.3% |
| 3 y3 years | -164.4% | -10000.0% | -430.2% |
| 5 y5 years | -69.3% | -10000.0% | -430.2% |
VYNE Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -466.1% | at low | -125.4% | +92.3% | -408.3% | +21.5% |
| 5 y | 5-year | -164.4% | at low | -107.3% | +92.3% | -151.6% | +21.5% |
| alltime | all time | -164.4% | at low | -107.3% | +92.3% | -151.6% | +24.5% |
VYNE Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.82 M(-125.4%) | -$51.73 M(+10.3%) |
| Jun 2024 | - | $19.02 M(-632.9%) | -$46.90 M(-28.9%) |
| Mar 2024 | - | -$3.57 M(-94.3%) | -$65.92 M(+14.9%) |
| Dec 2023 | -$57.35 M(-466.1%) | -$62.35 M(<-9900.0%) | -$57.35 M(-1246.9%) |
| Sep 2023 | - | $0.00(0.0%) | $5.00 M(+1.7%) |
| Jun 2023 | - | $0.00(-100.0%) | $4.92 M(0.0%) |
| Mar 2023 | - | $5.00 M(>+9900.0%) | $4.92 M(-68.6%) |
| Dec 2022 | $15.67 M(+1425.5%) | $1000.00(-101.2%) | $15.67 M(+0.0%) |
| Sep 2022 | - | -$86.00 K(<-9900.0%) | $15.67 M(-0.5%) |
| Jun 2022 | - | $0.00(-100.0%) | $15.75 M(-6.1%) |
| Mar 2022 | - | $15.75 M(>+9900.0%) | $16.78 M(+1533.8%) |
| Dec 2021 | $1.03 M(-98.8%) | $0.00(0.0%) | $1.03 M(-66.1%) |
| Sep 2021 | - | $0.00(-100.0%) | $3.03 M(0.0%) |
| Jun 2021 | - | $1.03 M(>+9900.0%) | $3.03 M(-86.9%) |
| Mar 2021 | - | $0.00(-100.0%) | $23.13 M(-74.0%) |
| Dec 2020 | $89.11 M | $2.00 M(>+9900.0%) | $89.11 M(-11.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $0.00(-100.0%) | $100.18 M(+17.1%) |
| Jun 2020 | - | $21.13 M(-68.0%) | $85.57 M(+7.2%) |
| Mar 2020 | - | $65.98 M(+404.7%) | $79.86 M(+93.0%) |
| Dec 2019 | $41.37 M(-222.1%) | $13.07 M(-189.5%) | $41.37 M(+70.8%) |
| Sep 2019 | - | -$14.61 M(-194.8%) | $24.23 M(-48.6%) |
| Jun 2019 | - | $15.41 M(-44.0%) | $47.13 M(+19.4%) |
| Mar 2019 | - | $27.50 M(-775.4%) | $39.49 M(-216.6%) |
| Dec 2018 | -$33.88 M(+124.5%) | -$4.07 M(-149.1%) | -$33.88 M(+44.0%) |
| Sep 2018 | - | $8.30 M(+6.8%) | -$23.53 M(-65.5%) |
| Jun 2018 | - | $7.76 M(-116.9%) | -$68.13 M(-0.6%) |
| Mar 2018 | - | -$45.87 M(-830.9%) | -$68.54 M(+354.2%) |
| Dec 2017 | -$15.09 M(-59.8%) | $6.28 M(-117.3%) | -$15.09 M(-29.4%) |
| Sep 2017 | - | -$36.30 M(-594.0%) | -$21.36 M(-243.0%) |
| Jun 2017 | - | $7.35 M(-3.1%) | $14.94 M(+96.9%) |
| Mar 2017 | - | $7.59 M | $7.59 M |
| Dec 2016 | -$37.52 M | - | - |
FAQ
- What is VYNE Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for VYNE Therapeutics?
- What is VYNE Therapeutics annual CFI year-on-year change?
- What is VYNE Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly CFI year-on-year change?
- What is VYNE Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for VYNE Therapeutics?
- What is VYNE Therapeutics TTM CFI year-on-year change?
What is VYNE Therapeutics annual cash flow from investing activities?
The current annual CFI of VYNE is -$57.35 M
What is the all time high annual CFI for VYNE Therapeutics?
VYNE Therapeutics all-time high annual cash flow from investing activities is $89.11 M
What is VYNE Therapeutics annual CFI year-on-year change?
Over the past year, VYNE annual cash flow from investing activities has changed by -$73.02 M (-466.08%)
What is VYNE Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of VYNE is -$4.82 M
What is the all time high quarterly CFI for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly cash flow from investing activities is $65.98 M
What is VYNE Therapeutics quarterly CFI year-on-year change?
Over the past year, VYNE quarterly cash flow from investing activities has changed by -$23.84 M (-125.36%)
What is VYNE Therapeutics TTM cash flow from investing activities?
The current TTM CFI of VYNE is -$51.73 M
What is the all time high TTM CFI for VYNE Therapeutics?
VYNE Therapeutics all-time high TTM cash flow from investing activities is $100.18 M
What is VYNE Therapeutics TTM CFI year-on-year change?
Over the past year, VYNE TTM cash flow from investing activities has changed by -$4.82 M (-10.29%)